While the observed loss of CD4+ T cell-associated HIV-1 DNA and RNA from the individual who received multiple cycles of brentuximab vedotin is only anecdotal, this case finding inspired the detailed ex vivo work of CD30 as a potential marker for HIV-1 infection as described above. This evidence concerns the gene CD4 and HIV-1 infection.